Consensus Black Diamond Therapeutics, Inc. OTC Markets

Stocks

BDTX

US09203E1055

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-06	Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Index	CI

9a3b77fd0b05.axksB6oZCJtLnuKT9AThyKpuReUdD6D9qKuAlA_yOCs.OGEUWNxNe9cqy4TGl3SmgfI-I5IwOdik5JPP4naAcmkbeHY3yUlyqD3ciQ~d7ab3524fcef7c5f5a49b01cf52fbf51

Analysts' recommendations: Black Diamond Therapeutics, Inc.

03-17	Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating	MT
07/08/25	Black Diamond Therapeutics Q2 net loss narrows as costs drop	RE
07/03/25	Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating	MT
31/07/24	Raymond James Initiates Black Diamond Therapeutics at Outperform	MT
16/05/24	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT
08/04/24	Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating	MT
14/07/23	Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target	MT
30/06/23	Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2	MT
28/06/23	HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11	MT
27/06/23	Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3	MT
12/05/22	Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating	MT
01/04/22	Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating	MT
29/03/22	Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22	MT
22/03/22	HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy	MT
18/03/22	Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating	MT
30/09/21	Black Diamond Therapeutics : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target	MT
17/08/21	Black Diamond Therapeutics : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating	MT
17/08/21	Black Diamond Therapeutics : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating	MT
21/05/21	Black Diamond Therapeutics : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48	MT
29/03/21	Black Diamond Therapeutics : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48	MT
26/03/21	Black Diamond Therapeutics : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating	MT
07/01/21	Black Diamond Therapeutics : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target	MT
24/11/20	Black Diamond Therapeutics : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
BLACK DIAMOND THERAPEUTICS, INC.	-	-	-	-
WUXI APPTEC CO., LTD.				+23.69%
ARGENX SE				+18.14%
INSMED INCORPORATED				+54.69%
WUXI BIOLOGICS (CAYMAN) INC.				+23.66%
BIONTECH SE				+23.2%
GENMAB A/S				+17.29%
PHARMAESSENTIA CORPORATION				+9.16%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				+32.94%
SUMMIT THERAPEUTICS INC.				+66.2%
Average				+29.89%
Weighted average by Cap.				+26.94%